Umoja Biopharma to Present Three Posters Data on its Integrated In Vivo CAR T and ShRED Platform Technologies at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
yahoo.com
news
2022-10-19 12:00:00

Umoja Biopharma, Inc.

SEATTLE, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo to treat patients with solid and hematologic malignancies, announced today that it will have three poster presentations at the 2022 Society for Immunotherapy for Cancer 37th Annual Meeting, to be held November 11-14, 2022 in Boston, Mass.



The presentations will highlight Umoja's complementary cell therapy platforms for in vivo CAR T-cell therapeutics and RACR-induced cytotoxic lymphocytes (iCIL).
